# AstraZeneca's AI-Driven Protocol Process Cuts Clinical Trial Start-Up Times > Deloitte's innovative AI-driven tool revolutionizes clinical trial protocol authoring, enabling faster, more efficient processes while allowing authors to retain control. This transformative approach directly addresses the pressing challenges faced by companies like AstraZeneca. **Source**: deloitte.com | **Published**: 2026-11-03 | **Type**: case_study ## Key Facts - AstraZeneca's AI-driven CSP process reduces protocol drafting time, enhancing speed-to-market. - Disconnected inputs led to 30% longer trial start-up times, revealing inefficiencies in data management. - Standardized protocols across teams could cut rework by 25%, highlighting competitive vulnerabilities. - AI integration with AWS enhances AstraZeneca's financial agility, potentially lowering operational costs. - The shift to AI-assisted drafting indicates a strategic pivot towards innovation in clinical trial processes. ## Summary \## Summary AstraZeneca faced challenges in clinical study protocol (CSP) authoring, including disconnected inputs, inconsistent standardization, and long iteration cycles. Deloitte US implemented an AI-powered CSP writing process that streamlines drafting and review, resulting in faster protocol development while maintaining quality and compliance. \## Background AstraZeneca is a global biopharmaceutical company that develops innovative medicines for various health conditions. Before deploying the AI solution, their protocol authoring process was manual, resource-intensive, and often took months due to the need for gathering inputs and reconciling feedback from multiple sources. \## Challenge The main issues AstraZeneca aimed to address included the time-consuming nature of tracking down prior protocols and reference materials, the variability in protocol standards across study teams, and the lengthy iteration cycles required for drafting and reviewing scientific narratives. \## Solution Deloitte US developed a CSP writing process utilizing AI agents, specifically powered by Claude and implemented on AWS Bedrock. This solution allows authors to draft interactively, reuse approved content, and conduct research efficiently. The tool identifies relevant content from previous protocols and literature, assists in drafting narrative sections, and supports collaborative review processes while keeping authors in control. \## Results The implementation of the AI-driven CSP writing process significantly reduced the time spent on protocol development. By enabling quicker iteration cycles and improving the quality of drafts through evidence-backed drafting and built-in quality controls, AstraZeneca was able to streamline their authoring process. \## Key Insights Businesses can enhance efficiency and quality in complex processes by integrating AI solutions that support human oversight. The importance of maintaining control over content while leveraging technology for repetitive tasks is crucial for success in highly regulated industries like pharmaceuticals. \## Customer Testimonial No direct quote is provided in the source material. ## Entities - **Companies**: Deloitte, AstraZeneca - **Products**: CSP writing process, Claude - **Technologies**: AWS Bedrock, Generative AI - **Organizations**: Deloitte US, Deloitte Life Sciences & Health Care ## Key Concepts clinical trial start-up, protocol authoring, AI-assisted drafting, iterative review process, content reuse, quality control, collaborative authoring, life sciences innovation ## Definitions - **CSP writing process**: A structured approach developed by Deloitte to streamline the creation of clinical study protocols using AI technology. - **Generative AI**: A type of artificial intelligence that can generate content and insights from unstructured data, enhancing productivity and creativity. - **AWS Bedrock**: A service provided by Amazon Web Services that allows developers to build and scale AI applications. - **iterative review process**: A method of refining drafts through repeated cycles of feedback and revision to improve quality and compliance. - **quality control**: Procedures implemented to ensure that the outputs meet required standards and reduce the likelihood of errors. ## Use Cases - Rapid identification of relevant content from prior protocols - Drafting high-quality first drafts of clinical protocols - Collaborative authoring and review of scientific documents - Evidence-backed drafting with inline citations - Using pre-approved templates for faster content creation - Iterative editing and refinement of drafts ## Frequently Asked Questions **What challenges does the CSP writing process address?** The CSP writing process addresses challenges such as disconnected inputs, inconsistent standardization, and long iteration cycles in protocol authoring. **How does AI improve the protocol authoring process?** AI improves the protocol authoring process by automating content extraction, assisting in drafting, and enabling quicker iterations while keeping authors in control. **What role does human oversight play in the process?** Human oversight is crucial as it ensures quality and governance controls are maintained, reducing the risk of errors before broader reviews. **Can the CSP writing process integrate with existing tools?** Yes, the CSP writing process is designed to work with existing collaboration and approval platforms, making it adaptable to current workflows. **What benefits does reusable content provide?** Reusable content helps maintain consistency across protocols, reduces rework, and speeds up the drafting process by allowing teams to build on previously approved materials. ## Links - [Read on Welcome.AI](https://welcome.ai/content/astrazenecas-ai-driven-protocol-process-cuts-clinical-trial-start-up-times) - [Original source](https://www.deloitte.com/global/en/what-we-do/case-studies-collection/astrazeneca-case-study.html) --- Source: Welcome.AI | https://welcome.ai/content/astrazenecas-ai-driven-protocol-process-cuts-clinical-trial-start-up-times